Craig Adam R — SEC insider filings
SEC reporting owner CIK 1339498. 18 insider filings on record with FilingPulse; latest filed 2026-10-19.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2021-03-12 to 2026-10-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 4 filings — 99,306 shares, $294,718 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 25 legs across 7 filings — 877,382 shares, $5,299,036 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 57.
- Largest priced transaction: sale of 242,300 shares @ $6.43 ($1,557,989) in CTI BIOPHARMA CORP, filed 2022-09-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| CTI BIOPHARMA CORP (CTIC) | President and CEO, Director | 13 | 3 legs · 8,500 sh · $32,837 | 24 legs · 829,946 sh · $5,088,207 | 53 |
| X4 Pharmaceuticals, Inc (XFOR) | Executive Chairman, Director | 5 | 2 legs · 90,806 sh · $261,881 | 1 leg · 47,436 sh · $210,829 | 4 |
Insider filings — Craig Adam R
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-19 | 4 | X4 Pharmaceuticals, Inc (XFOR) | Purchase (P): 4,600 @ $2.58 | EDGAR |
| 2026-08-13 | 4 | X4 Pharmaceuticals, Inc (XFOR) | Sale (S): 47,436 @ $4.44 | EDGAR |
| 2025-10-31 | 4 | X4 Pharmaceuticals, Inc (XFOR) | Grant/award (A): 2,329,154 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | X4 Pharmaceuticals, Inc (XFOR) | Purchase (P): 86,206 @ $2.90 | EDGAR |
| 2025-08-14 | 4 | X4 Pharmaceuticals, Inc (XFOR) | Grant/award (A): 289,881 @ $0 · Grant/award (A): 1,609,873 (derivative) @ $0 · Grant/award (A): 529,201 (derivative) @ $0 | EDGAR |
| 2023-06-26 | 4 | CTI BIOPHARMA CORP (CTIC) | Code (U): 31,470 @ $9.10 · Disposition to issuer (D): 1,200,000 (derivative) · Disposition to issuer (D): 450,000 (derivative) · Disposition to issuer (D): 475,000 (derivative) · Disposition to issuer (D): 600,000 (derivative) · Disposition to issuer (D): 470,054 (derivative) · +4 more | EDGAR |
| 2023-03-16 | 4 | CTI BIOPHARMA CORP (CTIC) | Grant/award (A): 900,000 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | CTI BIOPHARMA CORP (CTIC) | Option exercise (M): 83,200 @ $0.84 · Sale (S): 83,200 @ $6 · Option exercise (M): 2,117 @ $0.84 · Sale (S): 2,117 @ $6.01 · Option exercise (M): 83,200 (derivative) @ $0 · Option exercise (M): 2,117 (derivative) @ $0 | EDGAR |
| 2023-01-03 | 4 | CTI BIOPHARMA CORP (CTIC) | Option exercise (M): 13,800 @ $0.84 · Sale (S): 13,800 @ $6 · Grant/award (A): 1,579 @ $5.11 · Option exercise (M): 12,000 @ $0.84 · Sale (S): 12,000 @ $6 · Option exercise (M): 700 @ $0.84 · +10 more | EDGAR |
| 2022-11-14 | 4 | CTI BIOPHARMA CORP (CTIC) | Option exercise (M): 53,996 @ $0.84 · Sale (S): 46,100 @ $6 · Sale (S): 7,596 @ $6.01 · Sale (S): 300 @ $6.01 · Option exercise (M): 188,304 @ $0.84 · Sale (S): 136,408 @ $6 · +8 more | EDGAR |
| 2022-09-14 | 4 | CTI BIOPHARMA CORP (CTIC) | Option exercise (M): 242,300 @ $0.84 · Sale (S): 242,300 @ $6.43 · Option exercise (M): 242,300 (derivative) @ $0 | EDGAR |
| 2022-08-16 | 4 | CTI BIOPHARMA CORP (CTIC) | Purchase (P): 5,000 @ $5.50 | EDGAR |
| 2022-07-06 | 4 | CTI BIOPHARMA CORP (CTIC) | Grant/award (A): 6,183 @ $2.12 · Option exercise (M): 27,000 @ $0.84 · Sale (S): 27,000 @ $6 · Option exercise (M): 27,000 @ $0.84 · Sale (S): 27,000 @ $6 · Option exercise (M): 18,223 @ $0.84 · +4 more | EDGAR |
| 2022-06-03 | 4/A | CTI BIOPHARMA CORP (CTIC) | Option exercise (M): 27,000 (derivative) @ $0 · Option exercise (M): 27,000 (derivative) @ $0 · Option exercise (M): 18,223 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | CTI BIOPHARMA CORP (CTIC) | Option exercise (M): 27,000 @ $0.84 · Sale (S): 27,000 @ $6 · Option exercise (M): 27,000 @ $0.84 · Sale (S): 27,000 @ $6 · Option exercise (M): 18,223 @ $0.84 · Sale (S): 18,223 @ $6.01 · +3 more | EDGAR |
| 2022-03-11 | 4 | CTI BIOPHARMA CORP (CTIC) | Grant/award (A): 3,178 @ $2.11 · Grant/award (A): 1,115,000 (derivative) @ $0 | EDGAR |
| 2021-12-02 | 4 | CTI BIOPHARMA CORP (CTIC) | Grant/award (A): 5,000 @ $2.12 · Purchase (P): 1,322 @ $1.52 · Purchase (P): 2,178 @ $1.52 | EDGAR |
| 2021-03-12 | 4 | CTI BIOPHARMA CORP (CTIC) | Grant/award (A): 5,000 @ $0.98 · Grant/award (A): 800,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-03-08 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1339498 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs